Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Detection of γ-OHPdG in Circulating Tumor Cells of Patients With Hepatocellular Carcinoma as a Potential Prognostic Biomarker of Recurrence.
Aggarwal M, Kuo M, Zhu Z, Gould S, Zhang K, Johnson P, Beheshtian S, Kuhlman L, Zhao Z, Fang H, Kallakury B, Creswell K, Mueller S, Kroemer A, He AR, Chung FL. Aggarwal M, et al. Among authors: he ar. Gastro Hep Adv. 2024 Apr 24;3(6):809-820. doi: 10.1016/j.gastha.2024.04.006. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39280920 Free PMC article.
Intra-arterial locoregional therapies for intrahepatic cholangiocarcinoma.
Patel S, Hasanain A, Fang A, Khavandi MM, Mathias T, Cohen EI, Etezadi V, Sabri SS, Camacho JC, Yarmohammadi H, Banovac F, He AR, Radkani P, Habibollahi P, Nezami N. Patel S, et al. Among authors: he ar. Expert Rev Gastroenterol Hepatol. 2024 Sep;18(9):505-519. doi: 10.1080/17474124.2024.2402358. Epub 2024 Sep 17. Expert Rev Gastroenterol Hepatol. 2024. PMID: 39246149 Review.
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL. Lau G, et al. Among authors: he ar. J Hepatol. 2024 Jul 31:S0168-8278(24)02424-3. doi: 10.1016/j.jhep.2024.07.017. Online ahead of print. J Hepatol. 2024. PMID: 39089633 Free article.
Advances in Immunotherapy for Transplant Oncology.
Abdelrahim M, Esmail A, He AR, Khushman M, Rayyan Y. Abdelrahim M, et al. Among authors: he ar. Cancers (Basel). 2024 Jun 28;16(13):2369. doi: 10.3390/cancers16132369. Cancers (Basel). 2024. PMID: 39001431 Free PMC article.
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
Melero I, Yau T, Kang YK, Kim TY, Santoro A, Sangro B, Kudo M, Hou MM, Matilla A, Tovoli F, Knox J, He AR, El-Rayes B, Acosta-Rivera M, Lim HY, Soleymani S, Yao J, Neely J, Tschaika M, Hsu C, El-Khoueiry AB. Melero I, et al. Among authors: he ar. Ann Oncol. 2024 Jun;35(6):537-548. doi: 10.1016/j.annonc.2024.03.005. Epub 2024 May 22. Ann Oncol. 2024. PMID: 38844309 Free article. Clinical Trial.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, Valle JW. Oh DY, et al. Among authors: he ar. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29. Lancet Gastroenterol Hepatol. 2024. PMID: 38823398 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer.
Libbey N, Gallagher L, Cantalino J, Weinberg BA, Noel MS, He AR, Radkani P, Marshall JL, Weiner LM, Jackson PG, Fishbein TM, Winslow ER, Haddad N, Rashid A, Unger KR. Libbey N, et al. Among authors: he ar. J Gastrointest Cancer. 2024 Jun;55(2):852-861. doi: 10.1007/s12029-023-00996-3. Epub 2024 Feb 13. J Gastrointest Cancer. 2024. PMID: 38347342
102 results